September 20, 2025Frontiers in OncologyOpen Access

Treating and triggering hyperinflammation: tackling hemophagocytic lymphohistiocytosis and HLH-like syndromes in the pediatric cell therapy and critical care setting

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Review highlights the role of HCT and new cell therapies in combating hyperinflammation in HLH patients.

HCT is the only curative option for primary HLH, with ongoing challenges in managing associated hyperinflammation.
Secondary HLH can arise from various causes, requiring tailored approaches to manage inflammation and immune response.
New cellular therapies, like chimeric antigen receptor T cells, can provoke hyperinflammatory complications and need careful monitoring.
Effective management of HLH hinges on a thorough understanding of its pathophysiology and evolving treatment options.

Wobma et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

September 20, 2025Frontiers in OncologyOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Review highlights the role of HCT and new cell therapies in combating hyperinflammation in HLH patients.

HCT is the only curative option for primary HLH, with ongoing challenges in managing associated hyperinflammation.
Secondary HLH can arise from various causes, requiring tailored approaches to manage inflammation and immune response.
New cellular therapies, like chimeric antigen receptor T cells, can provoke hyperinflammatory complications and need careful monitoring.
Effective management of HLH hinges on a thorough understanding of its pathophysiology and evolving treatment options.

Wobma et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark